Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
Objective: Sacubitril/valsartan is a commonly used medicine for treating heart failure (HF) patients, but the treatment effects significantly vary. Neprilysin (NEP) and carboxylesterase 1 (CES1) play an important role in the efficacy of sacubitril/valsartan. The purpose of this study was to explore...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 79; no. 5; pp. 663 - 671 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
May2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=163150700&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 163150700 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: May2023 vid: 79 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 163150700 162726822 163150700 163150700 10.1007/s00228-023-03484-6 163150700 ppf: 663 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure. aug: au: Luo, Hong-Yu Gao, Li-Chen Long, Hui-Zhi Zhou, Zi-Wei Xu, Shuo-Guo Li, Feng-Jiao Li, Hong-Li Cheng, Yan Li, Cai-Xia Peng, Xing-Yu Li, Liang Chen, Ran Deng, Ping affil: School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, 421001, Hengyang, China sug: subj: Polymorphism, Genetic Drug Efficacy Patient Safety Valsartan Therapeutic Use Chinese Persons Heart Failure Human Genotype Polymorphism, Single Nucleotide Logistic Regression Haplotypes Odds Ratio Confidence Intervals Hypotension Funding Source ab: Objective: Sacubitril/valsartan is a commonly used medicine for treating heart failure (HF) patients, but the treatment effects significantly vary. Neprilysin (NEP) and carboxylesterase 1 (CES1) play an important role in the efficacy of sacubitril/valsartan. The purpose of this study was to explore the relationship between NEP and CES1 gene polymorphisms and the efficacy and safety of sacubitril/valsartan treatment in HF patients. Methods: Genotyping of 10 single nucleotide polymorphisms (SNPs) of the NEP and CES1 genes in 116 HF patients was performed by the Sequenom MassARRAY method, and logistic regression and haplotype analysis were used to evaluate the associations between SNPs and the clinical efficacy and safety of sacubitril/valsartan in HF patients. Results: A total of 116 Chinese patients with HF completed the whole trial, and T variations in rs701109 in NEP gene were an independent risk factor (P = 0.013, OR = 3.292, 95% CI:1.287–8.422) for the clinical efficacy of sacubitril/valsartan. Furthermore, haplotype analysis of 6 NEP SNPs (including rs701109) was performed and showed that the CGTACC and TGTACC haplotypes were significantly associated with clinical efficacy (OR = 0.095, 95%CI: 0.012–0.723, P = 0.003; OR = 5.586, 95% CI: 1.621–19.248, P = 0.005). Moreover, no association was found between SNPs of other selected genes in terms of efficacy in HF patients, and no association was observed between SNPs and symptomatic hypotension. Conclusion: Our results suggest an association between rs701109 and sacubitril/valsartan response in HF patients. Symptomatic hypotension is not associated with the presence of NEP polymorphisms. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|